Esketamine (CLE-100) vs SP-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
Esketamine (CLE-100)
Developed by Clexio Biosciences
NCT04103892 · Phase 2 · completed
The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.
Reported efficacy
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)
Result source: NCT06340958
SP-101
Developed by Synphatec (Shanghai) Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Esketamine (CLE-100) | SP-101 |
|---|---|---|
| MADRS, change (acute) | -10.7 vs -9.5−1.3 vs placeboNCT041038922 other results
| —Not reported |
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- Esketamine (CLE-100)
- -10.7 vs -9.5−1.3 vs placeboNCT04103892
2 other results
- -11.7 vs -8.7 NCT06340958
- -13.0 vs -7.7 NCT04103892
- SP-101
- —Not reported
CGI-S, change (acute)
- Esketamine (CLE-100)
- —Not reported
- SP-101
- —Not reported
MADRS response
- Esketamine (CLE-100)
- —Not reported
- SP-101
- —Not reported
MADRS remission
- Esketamine (CLE-100)
- —Not reported
- SP-101
- —Not reported
Relapse (% of patients)
- Esketamine (CLE-100)
- —Not reported
- SP-101
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SP-101: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Esketamine (CLE-100): 4 of 4 rows · SP-101: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Esketamine (CLE-100) |
|---|---|
| Dropout rate | 7.7%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results8.3%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 8% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Serious AEs | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | dizziness 30.8% (placebo 0%) somnolence 15.4% (placebo 0%) alanine aminotransferase increased 7.7% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more resultsdizziness 13.9% (placebo 0%) headache 12.5% (placebo 0%) somnolence 11.1% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 dizziness 18% (placebo 4.1%) nausea 18% (placebo 0%) headache 12% (placebo 2%) NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Esketamine (CLE-100)
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Esketamine (CLE-100)'s landscape · SP-101's landscape